US4330001060 - Common Stock
An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in obesity.
Should you consider HIMS & HERS HEALTH INC (NYSE:HIMS) for growth investing?
Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model.
Hims & Hers Health Inc. shares surged as much as 18% and are on track to close at fresh record after Hunterbrook Media said the company is poised to be a major beneficiary of President-elect Donald Trump’s nomination of Marty Makary to lead the Food and Drug Administration.
Is the food business the right business for Hims & Hers to be in?
On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83.
Hims & Hers has given back recent gains, but don't overlook the company's massive growth.
Hims & Hers Health Inc. shares dropped the most in their five-year history after Amazon.com Inc. said it would start marketing drugs to fight hair loss, an important component of the telehealth company’s business.